Wall Street brokerages expect STAAR Surgical Company (NASDAQ:STAA) to announce $0.03 earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for STAAR Surgical’s earnings. STAAR Surgical reported earnings of $0.02 per share during the same quarter last year, which would indicate a positive year over year growth rate of 50%. The firm is expected to announce its next quarterly earnings report on Thursday, March 1st.

According to Zacks, analysts expect that STAAR Surgical will report full-year earnings of ($0.02) per share for the current year, with EPS estimates ranging from ($0.06) to $0.02. For the next year, analysts expect that the firm will report earnings of $0.17 per share, with EPS estimates ranging from $0.15 to $0.19. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover STAAR Surgical.

Several brokerages have weighed in on STAA. Benchmark reissued a “buy” rating and set a $21.00 price objective on shares of STAAR Surgical in a report on Monday, November 20th. Canaccord Genuity increased their target price on STAAR Surgical from $17.50 to $20.00 and gave the stock a “buy” rating in a research report on Friday, November 17th. Zacks Investment Research downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. BidaskClub upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Finally, TheStreet upgraded STAAR Surgical from a “d+” rating to a “c” rating in a research report on Tuesday, August 15th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. STAAR Surgical has an average rating of “Buy” and a consensus target price of $17.67.

Shares of STAAR Surgical (NASDAQ STAA) traded down $0.70 during midday trading on Thursday, reaching $16.15. The company’s stock had a trading volume of 145,949 shares, compared to its average volume of 204,793. STAAR Surgical has a 1-year low of $8.95 and a 1-year high of $17.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.24 and a quick ratio of 1.72.

In other STAAR Surgical news, VP Keith Holliday sold 6,000 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total transaction of $99,900.00. Following the sale, the vice president now owns 45,969 shares in the company, valued at $765,383.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.60% of the company’s stock.

Several large investors have recently made changes to their positions in STAA. Teachers Advisors LLC grew its stake in shares of STAAR Surgical by 3.0% during the first quarter. Teachers Advisors LLC now owns 74,044 shares of the medical instruments supplier’s stock valued at $726,000 after buying an additional 2,162 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of STAAR Surgical by 1.5% in the first quarter. Vanguard Group Inc. now owns 1,272,972 shares of the medical instruments supplier’s stock worth $12,475,000 after purchasing an additional 18,621 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of STAAR Surgical by 6.3% in the first quarter. Geode Capital Management LLC now owns 245,080 shares of the medical instruments supplier’s stock worth $2,401,000 after purchasing an additional 14,420 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of STAAR Surgical by 18.6% in the first quarter. Renaissance Technologies LLC now owns 144,300 shares of the medical instruments supplier’s stock worth $1,414,000 after purchasing an additional 22,600 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of STAAR Surgical in the first quarter worth about $111,000. 77.73% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/12/10/zacks-analysts-expect-staar-surgical-company-staa-will-post-earnings-of-0-03-per-share.html.

About STAAR Surgical

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Get a free copy of the Zacks research report on STAAR Surgical (STAA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.